For the approximately one-third of patients who present with metastatic disease, there are several FDA-approved drugs available, among them the multi-kinase inhibitors (e.g. sorafenib and sunitinib) [19] and the mammalian target of rapamycin (mTOR) inhibitors [20]. This evidence concerns the gene MTOR and metastatic neoplasm.